{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:09:10Z","timestamp":1789002550871,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001381","name":"National Research Foundation Singapore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001381","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001459","name":"Ministry of Education - Singapore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001459","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011738","name":"Lee Kong Chian School of Medicine, Nanyang Technological University","doi-asserted-by":"publisher","award":["Vascular Research Initiative"],"award-info":[{"award-number":["Vascular Research Initiative"]}],"id":[{"id":"10.13039\/501100011738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"DOI":"10.1186\/s13287-026-05130-1","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:35:08Z","timestamp":1782408908000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Endothelial\u2013immune cells-on-chip for multiplex evaluation of drug responses through patient plasma screening"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0576-7377","authenticated-orcid":false,"given":"Khang Leng","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6806-6343","authenticated-orcid":false,"given":"Hannah Su-Ann","family":"Wee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi Yi","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui Min","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying Jie","family":"Chee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice Xiang Xuan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yock Young","family":"Dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Muthiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinkoo","family":"Dalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Wei","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7127-9107","authenticated-orcid":false,"given":"Christine","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"5130_CR1","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth GA, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990\u20132019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76:2982\u20133021. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.010.","journal-title":"J Am Coll Cardiol"},{"key":"5130_CR2","doi-asserted-by":"publisher","unstructured":"Goh RSJ, et al. The burden of cardiovascular disease in Asia from 2025 to 2050: a forecast analysis for East Asia, South Asia, South-East Asia, Central Asia, and high-income Asia Pacific regions. Lancet Reg Health \u2013 Western Pac. 2024;49. https:\/\/doi.org\/10.1016\/j.lanwpc.2024.101138.","DOI":"10.1016\/j.lanwpc.2024.101138"},{"key":"5130_CR3","doi-asserted-by":"publisher","unstructured":"Gallo G, Savoia C. New Insights into Endothelial Dysfunction in Cardiometabolic Diseases: Potential Mechanisms and Clinical Implications. Int J Mol Sci. 2024;25. https:\/\/doi.org\/10.3390\/ijms25052973.","DOI":"10.3390\/ijms25052973"},{"key":"5130_CR4","doi-asserted-by":"publisher","unstructured":"Wilcox T, Block CD, Schwartzbard AZ, Newman JD. Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists. JACC 75, 1956\u20131974 (2020). https:\/\/doi.org\/10.1016\/j.jacc.2020.02.056","DOI":"10.1016\/j.jacc.2020.02.056"},{"key":"5130_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1161\/CIRCRESAHA.116.310527","volume":"120","author":"PM Ridker","year":"2017","unstructured":"Ridker PM. How Common Is Residual Inflammatory Risk? Circul Res. 2017;120:617\u20139. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.310527.","journal-title":"Circul Res"},{"key":"5130_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11892-018-1011-7","volume":"18","author":"DZ Khat","year":"2018","unstructured":"Khat DZ, Husain M. Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA. Curr Diab Rep. 2018;18:45. https:\/\/doi.org\/10.1007\/s11892-018-1011-7.","journal-title":"Curr Diab Rep"},{"key":"5130_CR7","doi-asserted-by":"publisher","first-page":"777861","DOI":"10.3389\/fmed.2021.777861","volume":"8","author":"JI Fonseca-Correa","year":"2021","unstructured":"Fonseca-Correa JI, Correa-Rotter R, Sodium-Glucose. Cotransporter 2 Inhibitors Mechanisms of Action: A Review. Front Med (Lausanne). 2021;8:777861. https:\/\/doi.org\/10.3389\/fmed.2021.777861.","journal-title":"Front Med (Lausanne)"},{"key":"5130_CR8","doi-asserted-by":"publisher","unstructured":"Mirarchi L, et al. SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2022;23. https:\/\/doi.org\/10.3390\/ijms23073668.","DOI":"10.3390\/ijms23073668"},{"key":"5130_CR9","doi-asserted-by":"publisher","first-page":"14379","DOI":"10.1074\/jbc.REV120.008387","volume":"295","author":"RJ Perry","year":"2020","unstructured":"Perry RJ, Shulman GI. Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks. J Biol Chem. 2020;295:14379\u201390. https:\/\/doi.org\/10.1074\/jbc.REV120.008387.","journal-title":"J Biol Chem"},{"key":"5130_CR10","doi-asserted-by":"publisher","unstructured":"Takata T, Isomoto H. Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control. Int J Mol Sci. 2021;22. https:\/\/doi.org\/10.3390\/ijms22094374.","DOI":"10.3390\/ijms22094374"},{"key":"5130_CR11","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61:2108\u201317. https:\/\/doi.org\/10.1007\/s00125-018-4670-7.","journal-title":"Diabetologia"},{"key":"5130_CR12","doi-asserted-by":"publisher","unstructured":"Wei Q, Xu X, Guo L, Li J, Li L. Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. Front Endocrinol. 2021;12. https:\/\/doi.org\/10.3389\/fendo.2021.635556.","DOI":"10.3389\/fendo.2021.635556"},{"key":"5130_CR13","doi-asserted-by":"publisher","unstructured":"Liu H, Evaluation of, Fibrosis MASLD et al. FIB-4 and APRI Score in MASLD Combined with T2DM and MACCEs Receiving SGLT2 Inhibitors Treatment. Int J Gen Med 17, 2613\u20132625 (2024). https:\/\/doi.org\/10.2147\/ijgm.S460200","DOI":"10.2147\/ijgm.S460200"},{"key":"5130_CR14","doi-asserted-by":"publisher","unstructured":"Androutsakos T, et al. SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection. Int J Mol Sci. 2022;23. https:\/\/doi.org\/10.3390\/ijms23063107.","DOI":"10.3390\/ijms23063107"},{"key":"5130_CR15","doi-asserted-by":"publisher","unstructured":"Lin J, et al. Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial. BMJ. 2025;389(e083735). https:\/\/doi.org\/10.1136\/bmj-2024-083735.","DOI":"10.1136\/bmj-2024-083735"},{"key":"5130_CR16","doi-asserted-by":"publisher","unstructured":"Velliou RI, Giannousi E, Ralliou C, Kassi E, Chatzigeorgiou A. Ex Vivo Tools and Models in MASLD Research. Cells. 2024;13. https:\/\/doi.org\/10.3390\/cells13221827.","DOI":"10.3390\/cells13221827"},{"key":"5130_CR17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/s41576-022-00466-9","volume":"23","author":"DE Ingber","year":"2022","unstructured":"Ingber DE. Human organs-on-chips for disease modelling, drug development and personalized medicine. Nat Rev Genet. 2022;23:467\u201391. https:\/\/doi.org\/10.1038\/s41576-022-00466-9.","journal-title":"Nat Rev Genet"},{"key":"5130_CR18","doi-asserted-by":"publisher","unstructured":"Tham N et al. Digital Twin Metabolic Flux Profiling Enables Precise Prediction of Therapeutic Outcomes in Type 2 Diabetes. medRxiv, 2025.2012.2004.25341430 (2025). https:\/\/doi.org\/10.64898\/2025.12.04.25341430","DOI":"10.64898\/2025.12.04.25341430"},{"key":"5130_CR19","doi-asserted-by":"publisher","first-page":"e55871","DOI":"10.15252\/embr.202255871","volume":"23","author":"CY Ng","year":"2022","unstructured":"Ng CY, et al. Endothelial-immune crosstalk contributes to vasculopathy in nonalcoholic fatty liver disease. EMBO Rep. 2022;23:e55871. https:\/\/doi.org\/10.15252\/embr.202255871.","journal-title":"EMBO Rep"},{"key":"5130_CR20","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/cvr\/cvae047","volume":"120","author":"A Preda","year":"2024","unstructured":"Preda A, et al. SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits. Cardiovascular Res. 2024;120:443\u201360. https:\/\/doi.org\/10.1093\/cvr\/cvae047.","journal-title":"Cardiovascular Res"},{"key":"5130_CR21","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/hr.2009.228","volume":"33","author":"S Czernichow","year":"2010","unstructured":"Czernichow S, et al. Macrovascular and microvascular dysfunction in the metabolic syndrome. Hypertens Res. 2010;33:293\u20137. https:\/\/doi.org\/10.1038\/hr.2009.228.","journal-title":"Hypertens Res"},{"key":"5130_CR22","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s10020-024-01019-y","volume":"30","author":"MS Islam","year":"2024","unstructured":"Islam MS, et al. The interplay of factors in metabolic syndrome: understanding its roots and complexity. Mol Med. 2024;30:279. https:\/\/doi.org\/10.1186\/s10020-024-01019-y.","journal-title":"Mol Med"},{"key":"5130_CR23","doi-asserted-by":"publisher","unstructured":"Tran V, et al. The Vascular Consequences of Metabolic Syndrome: Rodent Models, Endothelial Dysfunction, and Current Therapies. Front Pharmacol. 2020;11\u20132020. https:\/\/doi.org\/10.3389\/fphar.2020.00148.","DOI":"10.3389\/fphar.2020.00148"},{"key":"5130_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.semcdb.2023.05.001","volume":"155","author":"CY Ng","year":"2024","unstructured":"Ng CY, Cheung C. Origins and functional differences of blood endothelial cells. Semin Cell Dev Biol. 2024;155:23\u20139. https:\/\/doi.org\/10.1016\/j.semcdb.2023.05.001.","journal-title":"Semin Cell Dev Biol"},{"key":"5130_CR25","doi-asserted-by":"publisher","unstructured":"Mroueh A, et al. SGLT2 expression in the left ventricle of cardiac patients is correlated with low-grade inflammation involving the pro-oxidant AT1R\/NADPH oxidases\/SGLT2 crosstalk: potential role in heart failure. Eur Heart J. 2023;44. https:\/\/doi.org\/10.1093\/eurheartj\/ehad655.3150.","DOI":"10.1093\/eurheartj\/ehad655.3150"},{"key":"5130_CR26","doi-asserted-by":"publisher","unstructured":"Dutzmann J, et al. Empagliflozin prevents neointima formation by impairing smooth muscle cell proliferation and accelerating endothelial regeneration. Front Cardiovasc Med. 2022;9\u20132022. https:\/\/doi.org\/10.3389\/fcvm.2022.956041.","DOI":"10.3389\/fcvm.2022.956041"},{"key":"5130_CR27","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.1038\/s41591-024-03376-x","volume":"30","author":"SN Barnett","year":"2024","unstructured":"Barnett SN, et al. An organotypic atlas of human vascular cells. Nat Med. 2024;30:3468\u201381. https:\/\/doi.org\/10.1038\/s41591-024-03376-x.","journal-title":"Nat Med"},{"key":"5130_CR28","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.3390\/jcm12041356","volume":"12","author":"D Semo","year":"2023","unstructured":"Semo D, et al. The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms. J Clin Med. 2023;12:1356.","journal-title":"J Clin Med"},{"key":"5130_CR29","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41577-022-00694-4","volume":"22","author":"J Amersfoort","year":"2022","unstructured":"Amersfoort J, Eelen G, Carmeliet P. Immunomodulation by endothelial cells - partnering up with the immune system? Nat Rev Immunol. 2022;22:576\u201388. https:\/\/doi.org\/10.1038\/s41577-022-00694-4.","journal-title":"Nat Rev Immunol"},{"key":"5130_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/imr.13354","volume":"324","author":"Y Valentine","year":"2024","unstructured":"Valentine Y, Nikolajczyk BS. T cells in obesity-associated inflammation: The devil is in the details. Immunol Rev. 2024;324:25\u201341. https:\/\/doi.org\/10.1111\/imr.13354.","journal-title":"Immunol Rev"},{"key":"5130_CR31","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1161\/ATVBAHA.114.304636","volume":"34","author":"T McLaughlin","year":"2014","unstructured":"McLaughlin T, et al. T-cell profile in adipose tissue is associated with insulin resistance and systemic inflammation in humans. Arterioscler Thromb Vasc Biol. 2014;34:2637\u201343. https:\/\/doi.org\/10.1161\/ATVBAHA.114.304636.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5130_CR32","doi-asserted-by":"publisher","unstructured":"Sluiter TJ, van Buul JD, Huveneers S, Quax PHA, de Vries MR. Endothelial Barrier Function and Leukocyte Transmigration in Atherosclerosis. Biomedicines. 2021;9. https:\/\/doi.org\/10.3390\/biomedicines9040328.","DOI":"10.3390\/biomedicines9040328"},{"key":"5130_CR33","doi-asserted-by":"publisher","first-page":"e978720","DOI":"10.4161\/21688370.2014.978720","volume":"3","author":"SF Rodrigues","year":"2015","unstructured":"Rodrigues SF, Granger DN. Blood cells and endothelial barrier function. Tissue Barriers. 2015;3:e978720. https:\/\/doi.org\/10.4161\/21688370.2014.978720.","journal-title":"Tissue Barriers"},{"issue":"1","key":"5130_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.14290","volume":"23","author":"S Sarma","year":"2021","unstructured":"Sarma S, Sockalingam S, Dash S. Obesity as a multisystem disease: Trends in obesity rates and obesity-related complications. Diabetes Obes Metab. 2021;23(1):3\u201316. https:\/\/doi.org\/10.1111\/dom.14290.","journal-title":"Diabetes Obes Metab"},{"key":"5130_CR35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.eprac.2022.10.007","volume":"29","author":"CE Fu","year":"2023","unstructured":"Fu CE, et al. A Meta-analysis on Associated Risk of Mortality in Nonalcoholic Fatty Liver Disease. Endocr Pract. 2023;29:33\u20139. https:\/\/doi.org\/10.1016\/j.eprac.2022.10.007. https:\/\/doi.org:.","journal-title":"Endocr Pract"},{"key":"5130_CR36","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s12933-024-02434-5","volume":"23","author":"H Zheng","year":"2024","unstructured":"Zheng H, Sechi LA, Navarese EP, Casu G, Vidili G. Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review. Cardiovasc Diabetol. 2024;23:346. https:\/\/doi.org\/10.1186\/s12933-024-02434-5.","journal-title":"Cardiovasc Diabetol"},{"key":"5130_CR37","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1039\/d1lc00131k","volume":"21","author":"C Su","year":"2021","unstructured":"Su C, et al. A novel human arterial wall-on-a-chip to study endothelial inflammation and vascular smooth muscle cell migration in early atherosclerosis. Lab Chip. 2021;21:2359\u201371. https:\/\/doi.org\/10.1039\/d1lc00131k.","journal-title":"Lab Chip"},{"key":"5130_CR38","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.actbio.2021.07.013","volume":"134","author":"K Du","year":"2021","unstructured":"Du K, et al. Modeling nonalcoholic fatty liver disease on a liver lobule chip with dual blood supply. Acta Biomater. 2021;134:228\u201339. https:\/\/doi.org\/10.1016\/j.actbio.2021.07.013. https:\/\/doi.org:.","journal-title":"Acta Biomater"},{"key":"5130_CR39","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/hep4.1647","volume":"5","author":"MS Freag","year":"2021","unstructured":"Freag MS, et al. Human Nonalcoholic Steatohepatitis on a Chip. Hepatol Commun. 2021;5:217\u201333. https:\/\/doi.org\/10.1002\/hep4.1647.","journal-title":"Hepatol Commun"},{"key":"5130_CR40","doi-asserted-by":"publisher","first-page":"e1901379","DOI":"10.1002\/adhm.201901379","volume":"8","author":"CE Suurmond","year":"2019","unstructured":"Suurmond CE, et al. In Vitro Human Liver Model of Nonalcoholic Steatohepatitis by Coculturing Hepatocytes, Endothelial Cells, and Kupffer Cells. Adv Healthc Mater. 2019;8:e1901379. https:\/\/doi.org\/10.1002\/adhm.201901379.","journal-title":"Adv Healthc Mater"},{"key":"5130_CR41","doi-asserted-by":"publisher","first-page":"5734","DOI":"10.1021\/acsbiomaterials.0c00682","volume":"6","author":"Y Wang","year":"2020","unstructured":"Wang Y, et al. Modeling Human Nonalcoholic Fatty Liver Disease (NAFLD) with an Organoids-on-a-Chip System. ACS Biomaterials Sci Eng. 2020;6:5734\u201343. https:\/\/doi.org\/10.1021\/acsbiomaterials.0c00682.","journal-title":"ACS Biomaterials Sci Eng"},{"key":"5130_CR42","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s13679-025-00657-5","volume":"14","author":"ID Vachliotis","year":"2025","unstructured":"Vachliotis ID, Polyzos SA. The Intriguing Roles of Cytokines in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review. Curr Obes Rep. 2025;14:65. https:\/\/doi.org\/10.1007\/s13679-025-00657-5.","journal-title":"Curr Obes Rep"},{"key":"5130_CR43","doi-asserted-by":"publisher","first-page":"e651","DOI":"10.1002\/mco2.651","volume":"5","author":"X Wang","year":"2024","unstructured":"Wang X, He B. Endothelial dysfunction: molecular mechanisms and clinical implications. MedComm (2020). 2024;5:e651. https:\/\/doi.org\/10.1002\/mco2.651.","journal-title":"MedComm (2020)"},{"key":"5130_CR44","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jacasi.2022.03.009","volume":"2","author":"Y Kubota","year":"2022","unstructured":"Kubota Y, Shimizu W. Clinical Benefits of Sodium\u2013Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects. JACC: Asia. 2022;2:287\u201393. https:\/\/doi.org\/10.1016\/j.jacasi.2022.03.009. https:\/\/doi.org:.","journal-title":"JACC: Asia"},{"key":"5130_CR45","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1016\/j.cmet.2023.10.009","volume":"35","author":"K Sawada","year":"2023","unstructured":"Sawada K, Chung H, Softic S, Moreno-Fernandez ME, Divanovic S. The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease. Cell Metab. 2023;35:1852\u201371. https:\/\/doi.org\/10.1016\/j.cmet.2023.10.009.","journal-title":"Cell Metab"},{"key":"5130_CR46","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1038\/s41591-019-0590-4","volume":"25","author":"DM Fernandez","year":"2019","unstructured":"Fernandez DM, et al. Single-cell immune landscape of human atherosclerotic plaques. Nat Med. 2019;25:1576\u201388. https:\/\/doi.org\/10.1038\/s41591-019-0590-4.","journal-title":"Nat Med"},{"key":"5130_CR47","doi-asserted-by":"publisher","unstructured":"Qiu L, Kong B, Kong T, Wang H. Recent advances in liver-on-chips: Design, fabrication, and applications. Smart Medicine 2, e20220010 (2023). https:\/\/doi.org:https:\/\/doi.org\/10.1002\/SMMD.20220010","DOI":"10.1002\/SMMD.20220010"},{"key":"5130_CR48","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jcmgh.2022.11.008","volume":"15","author":"S Kaur","year":"2023","unstructured":"Kaur S, et al. In Vitro Models for the Study of Liver Biology and Diseases: Advances and Limitations. Cell Mol Gastroenterol Hepatol. 2023;15:559\u201371. https:\/\/doi.org\/10.1016\/j.jcmgh.2022.11.008.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"5130_CR49","doi-asserted-by":"publisher","unstructured":"Wang R, et al. Current progress of in vitro vascular models on microfluidic chips. Biofabrication. 2025;17. https:\/\/doi.org\/10.1088\/1758-5090\/adb182.","DOI":"10.1088\/1758-5090\/adb182"},{"key":"5130_CR50","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1038\/s41598-025-85987-z","volume":"15","author":"I Linares","year":"2025","unstructured":"Linares I, et al. Fluid flow impacts endothelial-monocyte interactions in a model of vascular inflammatory fibrosis. Sci Rep. 2025;15:3227. https:\/\/doi.org\/10.1038\/s41598-025-85987-z.","journal-title":"Sci Rep"},{"key":"5130_CR51","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1039\/c7lc00607a","volume":"17","author":"NV Menon","year":"2017","unstructured":"Menon NV, Tay HM, Wee SN, Li KHH, Hou HW. Micro-engineered perfusable 3D vasculatures for cardiovascular diseases. Lab Chip. 2017;17:2960\u20138. https:\/\/doi.org\/10.1039\/c7lc00607a.","journal-title":"Lab Chip"},{"key":"5130_CR52","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nri1330","volume":"4","author":"RT Abraham","year":"2004","unstructured":"Abraham RT, Weiss A. Jurkat T cells and development of the T-cell receptor signalling paradigm. Nat Rev Immunol. 2004;4:301\u20138. https:\/\/doi.org\/10.1038\/nri1330.","journal-title":"Nat Rev Immunol"},{"key":"5130_CR53","doi-asserted-by":"publisher","first-page":"30452","DOI":"10.1038\/srep30452","volume":"6","author":"Q Li","year":"2016","unstructured":"Li Q, Huth S, Adam D, Selhuber-Unkel C. Reinforcement of integrin-mediated T-Lymphocyte adhesion by TNF-induced Inside-out Signaling. Sci Rep. 2016;6:30452. https:\/\/doi.org\/10.1038\/srep30452.","journal-title":"Sci Rep"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-026-05130-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05130-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05130-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:05:33Z","timestamp":1789002333000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13287-026-05130-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5130"],"URL":"https:\/\/doi.org\/10.1186\/s13287-026-05130-1","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"17 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The project \u201cEffects of Dapagliflozin and Metformin on Vascular Function in Newly Diagnosed Treatment-Na\u00efve Type 2 Diabetes \u2013 A Randomized Controlled Trial (DMVascular Study)\u201d was performed at Tan Tock Seng Hospital in Singapore and was approved by the National Healthcare Group Ethics Board (DSRB reference: 2018\u2009\u2212\u200900899) on March 10, 2023.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"<b>Declarations<\/b>"}},{"value":"M.D.M has served as a consultant to Roche, Astellas and Gilead, Perspectum, and Echosens. He also serves as the CMO of LiverGENIX PTE LTD. All the other authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"<b>Declarations<\/b>"}}],"article-number":"313"}}